



ASX ANNOUNCEMENT

Lumos Completes Closure of Sarasota Facility

MELBOURNE, Australia (3 October 2022) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) is pleased to announce it has successfully completed the closure of its Sarasota Facility and relocated the Company’s manufacturing capability to its Carlsbad site in California.

In August 2022 Lumos announced its intention to close its Sarasota facility as part of an ongoing program to reduce the Company’s cash burn and future investment commitments. This has now been completed and Lumos’ lease obligations for the Sarasota finished on 30 September. Lumos was able to successfully negotiate a termination of the lease for the site with a final, single payment of US\$0.3 million that has relieved the Company of more than US\$3.1 million in future lease payment obligations, and additional facility running costs. The wind-up payment is expected to be offset by the proceeds from the sale or return of assets from Lumos’ Sarasota facility. Lumos has transferred equipment and key personnel for its manufacturing production line to the Company’s facility in Carlsbad where it has now been established and installation has been completed.

“Closing a facility, such as the one we had established in Sarasota, is not a trivial exercise and I am delighted that we were able to successfully achieve this within the short timeframe that we were targeting,” said Doug Ward, Chief Executive Officer of Lumos Diagnostics. “We now have a single operational facility, located in Carlsbad, that can provide everything from product development services through to commercial-scale manufacturing for our clients. Despite its complexity, this has ended up being a remarkably seamless transition that has not resulted in any disruption to our operations, which is critical as we continue to build our pipeline of commercial projects.”

This announcement has been approved by the Lumos Disclosure Committee

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or febridx.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598